Objective: To evaluate the clinical outcome of Botulinum toxin A(BTX-A) with oral baclofen for patients with detrusor overactivity secondary to spinal cord injury(SCI). Methods: A total of 9 SCI patients (mean age, 32 years ;male 7, female 2) with urodynamic detrusor overactivity were included into the study between June 2017 and June 2019. All the patients received BTX-A intradetrusor injections and baclofen. Patients were evaluated at baseline, and 4 weeks after injection. The efficacy and safety outcomes included voiding diary, urodynamic data. Adverse events were also recorded. Results: Compared to the baseline data, the patients’ incontinence quality of life(I-QOL) score, mean maximum detrusor pressure (MDP) and mean maximum cystometric capacity (MCC) improved significantly at 4-week follow-up.No adverse and toxic effect was observed. Conclusions: The treatment of BTX-A with baclofen is effective and safe for patients with detrusor overactivity secondary to SCI. However, it is necessary to observe its long term outcome.